Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Baseline gene expression predicts TKI response in CML

Publish date:: September 16, 2020

Key clinical point: Baseline gene expression predicted tyrosine kinase inhibitor 5-year responder status in chronic myeloid leukemia patients.

Major finding: A gene-expression model predicted 5-year responder status (area under the curve, 0.76).

Study details: A exploratory analysis of 70 patient samples from the ENESTnd trial.

Disclosures: The study was sponsored by Novartis. Dr. Radich is a paid consultant for Genentech, Cepheid, Bristol-Myers Squibb, Takeda, and Novartis.

Citation:

Radich JP et al. SOHO 2020, Abstract CML-109.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CML

Survey quantifies COVID-19’s impact on oncology,

Baseline gene expression predicts TKI response in CML,

Inotuzumab/bosutinib treat R/R Ph+ ALL, CML in blast phase,

Complementary medicine use common among patients on TKIs,

Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.